



LUPIN LIMITED

Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011.

(₹ in Lakhs)

Particulars	Quarter Ended 30/06/2011 (Unaudited)	Quarter Ended 30/06/2010 (Unaudited)	Accounting Year Ended 31/03/2011 (Audited)
1) a) Sales (Gross)	110,532	100,849	446,160
Less: Excise Duty	1,108	697	3,535
Sales (Net)	109,424	100,152	442,625
b) Other Operating Income	1,154	784	8,225
2) Total	110,578	100,936	450,850
3) Expenditure			
a) (Increase)/Decrease in stock in trade and work-in-progress	(3,065)	1,763	(51)
b) Consumption of raw and packing materials	39,407	27,667	138,242
c) Purchase of traded goods	14,969	11,165	38,419
d) Employees cost	13,668	11,500	49,123
e) Depreciation and amortisation	2,889	2,683	10,428
f) Manufacturing and other expenses	34,230	28,508	127,853
Total	102,098	83,286	364,014
4) Profit from Operations before Other Income, Interest and Exceptional Items	8,480	17,650	86,836
5) Other Income	22	33	296
6) Profit before Interest and Exceptional Items	8,502	17,683	87,132
7) Interest and finance charges	448	666	2,569
8) Profit after Interest but before Exceptional Items	8,054	17,017	84,563
9) Exceptional items	-	-	-
10) Profit from Ordinary Activities before tax	8,054	17,017	84,563
11) Tax Expense (current and deferred)	779	1,275	3,565
12) Net Profit from Ordinary Activities after tax	7,275	15,742	80,998
13) Extraordinary items (net of tax expense)	-	-	-
14) Net Profit	7,275	15,742	80,998
15) Paid up equity share capital (Face value ₹ each) (Refer note 2 below)	8,926 (2/-)	8,900 (10/-)	8,924 (2/-)
16) Reserves excluding Revaluation Reserves			306,342
17) Earnings Per Share [EPS] (Not Annualised) ₹			
- Basic	1.63	3.54	18.18
- Diluted	1.62	3.52	18.07
(Refer note 2 below)			
18) Public Shareholding			
- Number of shares	236,695,259	47,068,311	236,573,649
- Percentage of shareholding	53.04	52.89	53.02
19) Promoters and promoter group shareholding			
a) Pledged/Encumbered		998,000	-
-Number of shares	-	-	-
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	2.38	-
-Percentage of shares (as a % of the total share capital of the Company)	-	1.12	-
b) Non-encumbered			
-Number of shares	209,602,340	40,933,508	209,627,540
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	97.62	100.00
-Percentage of shares (as a % of the total share capital of the Company)	46.96	45.99	46.98

continued on Page 2.


NOTES:

1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on July 27, 2011. The Statutory Auditors of the Company have carried out limited review of the above standalone results pursuant to clause 41 of the Listing Agreement.
2. Pursuant to the approval accorded at the Annual General Meeting of the members of the Company held on July 28, 2010 and upon completion of other regulatory formalities, one equity share of ₹ 10/- each was sub-divided into five equity shares of ₹ 2/- each fully paid-up. Accordingly, the Basic and Diluted Earnings Per Share (EPS) has been restated for the corresponding quarter to give effect of sub-division of shares in accordance with Accounting Standard 20 "Earnings Per Share".
3. During the quarter, 96,410 equity shares of ₹ 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans, resulting in an increase in the paid-up share capital by ₹ 2 lakhs and securities premium account by ₹ 93 lakhs.
4. The aggregate amount of revenue expenditure incurred on Research and Development as reflected under the respective heads of account is as under:

	Quarter Ended <u>30.06.2011</u>	Quarter Ended <u>30.06.2010</u>	Accounting Year Ended <u>31.03.2011</u>
₹ in Lakhs	9,276	9,354	43,109

5. The Company operates in one reportable business segment i.e. "Pharmaceuticals".
6. There was no unresolved investor complaint pending as on April 01, 2011. The Company received 5 complaints during the quarter which were resolved. There was no unresolved complaint pending as on June 30, 2011.
7. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

By order of the Board
For Lupin Limited



Dr. Desh Bandhu Gupta
Chairman

Place : Mumbai
Dated: July 27, 2011